Neuromedin U: A candidate biomarker and therapeutic target to predict and overcome resistance to HER-tyrosine kinase inhibitors

Cancer Research

Volumn 74, Issue 14, 2014, Pages 3821-3833

  Rani, Sweta ^a   Corcoran, Claire ^a   Shiels, Liam ^b   Germano, Serena ^a   Breslin, Susan ^a   Madden, Stephen ^c   McDermott, Martina S ^c   Browne, Brigid C ^c   O'Donovan, Norma ^c   Crown, John ^d   Gogarty, Martina ^a   Byrne, Annette T ^b,e   O'Driscoll, Lorraine ^a  

^a TRINITY COLLEGE DUBLIN   (Ireland)

^b ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

^c DUBLIN CITY UNIVERSITY   (Ireland)

^d ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

^e UNIVERSITY COLLEGE DUBLIN   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

AFATINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HEAT SHOCK PROTEIN 27; LAPATINIB; NERATINIB; NEUROMEDIN U; TRASTUZUMAB;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANOIKIS; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; ATTENUATION; BREAST CANCER; CANCER PROGNOSIS; CANCER RESISTANCE; CANCER SURVIVAL; CELL INVASION; CELL MOTILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFECT; DRUG TARGETING; HUMAN; HUMAN CELL; IC 50; MAJOR CLINICAL STUDY; MARKER GENE; MOUSE; NEUROMEDIN U GENE; NONHUMAN; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN STABILITY; RNA INTERFERENCE;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOLOGICAL TRANSPORT; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE KNOCKDOWN TECHNIQUES; HUMANS; NEOPLASM METASTASIS; NEUROPEPTIDES; PHENOTYPE; PROGNOSIS; PROTEIN KINASE INHIBITORS; RECEPTOR, ERBB-2; RNA, MESSENGER; TUMOR BURDEN; TUMOR MARKERS, BIOLOGICAL; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84904246276     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-13-2053     Document Type: Article

References (38)

1. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-82. (Pubitemid 17231334)
2. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989;244:707-12. (Pubitemid 19147683)
3. Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999;17:2639-48. (Pubitemid 29415219)
4. Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M, et al. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 2011;365:1273-83.
5. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-92. (Pubitemid 32222155)
6. Baselga J, Bradbury I, Eidtmann H, Di Cosimo S, de Azambuja E, Aura C, et al. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet 2012;379:633-40.
7. Rusnak DW, Lackey K, Affleck K, Wood ER, Alligood KJ, Rhodes N, et al. The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo. Mol Cancer Ther 2001;1:85-94.
8. Browne BC, O'Brien N, Duffy MJ, Crown J, O'Donovan N. HER-2 signaling and inhibition in breast cancer. Curr Cancer Drug Targets 2009;9:419-38.
9. Nahta R, Esteva FJ. Trastuzumab: triumphs and tribulations. Oncogene 2007;26:3637-43. (Pubitemid 46842713)
10. Liu L, Greger J, Shi H, Liu Y, Greshock J, Annan R, et al. Novel mechanism of lapatinib resistance in HER2-positive breast tumor cells: activation of AXL. Cancer Res 2009;69:6871-8.
11. Press MF, Finn RS, Cameron D, Di Leo A, Geyer CE, Villalobos IE, et al. HER-2 gene amplification, HER-2 and epidermal growth factor receptor mRNA and protein expression, and lapatinib ef fi cacy in women with metastatic breast cancer. Clin Cancer Res 2008;14:7861-70.
12. Wang YC, Morrison G, Gillihan R, Guo J, Ward RM, Fu X, et al. Different mechanisms for resistance to trastuzumab versus lapatinib in HER2- positive breast cancers-role of estrogen receptor and HER2 reactivation. Breast Cancer Res 2011;13:R121.
13. Rabindran SK, Discafani CM, Rosfjord EC, Baxter M, Floyd MB, Golas J, et al. Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase. Cancer Res 2004;64:3958-65. (Pubitemid 38697310)
14. Burstein HJ, Sun Y, Dirix LY, Jiang Z, Paridaens R, Tan AR, et al. Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer. J Clin Oncol 2010;10:1301-7.
15. Lin NU, Winer EP, Wheatley D, Carey LA, Houston S, Mendelson D, et al. A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab. Breast Cancer Res Treat 2012;133:1057- 65.
16. O'Driscoll L, Kenny E, De Villarreal MP, Clynes M. Detection of specific mRNAs in culture medium conditioned by human tumour cells: Potential for new class of cancer biomarkers in serum. Cancer Genomics - Proteomics 2005;2:43-52. (Pubitemid 40791360)
17. Friel AM, Corcoran C, Crown J, O'Driscoll L. Relevance of circulating tumor cells, extracellular nucleic acids & exosomes in breast cancer. Breast Cancer Res Treat 2010;123:613-25.
18. O'Driscoll L, Kenny E, Mehta JP, Doolan P, Joyce H, Gammell P, et al. Feasibility and relevance of global expression profiling of gene transcripts in serum from breast cancer patients using whole genome microarrays and quantitative RT-PCR. Cancer Genomics Proteomics 2008;5:94-104.
19. Rani S, Clynes M, O'Driscoll L. Detection of amplifiable mRNA extracellular to insulin-producing cells: potential for predicting beta cell mass and function. Clin Chem 2007;53:1936-44. (Pubitemid 350036038)
20. Rani S, O'Driscoll L. Reverse-transcriptase polymerase chain reaction to detect extracellular mRNAs. Methods Mol Biol 2011;784:15-25.
21. Minamino N, Kangawa K, Matsuo H. Neuromedin U-8 and U-25: novel uterus stimulating and hypertensive peptides identified in porcine spinal cord. Biochem Biophys Res Commun 1985;130:1078-85.
22. Budhiraja S, Chugh A. Neuromedin U: physiology, pharmacology and therapeutic potential. Fundam Clin Pharmacol 2009;23:149-57.
23. Mitchell JD, Maguire JJ, Davenport AP. Emerging pharmacology and physiology of neuromedin U and the structurally related peptide neuromedin S. Br J Pharmacol 2009;158:87-103.
24. O'Brien NA, Browne BC, Chow L, Wang Y, Ginther C, Arboleda J, et al. Activated phosphoinositide 3-kinase/AKT signaling confers resistance to trastuzumab but not lapatinib. Mol Cancer Ther 2010;9:1489-502.
25. Seoane S, Montero JC, Ocana A, Pandiella A. Effect of multikinase inhibitors on caspase-independent cell death and DNA damage in HER2-overexpressing breast cancer cells. J Natl Cancer Inst 2010;102:1432-46.
26. Hegde PS, Rusnak D, Bertiaux M, Alligood K, Strum J, Gagnon R, et al. Delineation of molecular mechanisms of sensitivity to lapatinib in breast cancer cell lines using global gene expression profiles. Mol Cancer Ther 2007;6:1629-40. (Pubitemid 46954030)
27. Narayan M, Wilken JA, Harris LN, Baron AT, Kimbler KD, Maihle NJ. Trastuzumab-induced HER reprogramming in "resistant" breast carcinoma cells. Cancer Res 2009;69:2191-4.
28. Zhang D, Tai LK, Wong LL, Chiu LL, Sethi SK, Koay ES. Proteomic study reveals that proteins involved in metabolic and detoxification pathways are highly expressed in HER-2/neu-positive breast cancer. Mol Cell Proteomics 2005;4:1686-96. (Pubitemid 41749262)
29. Kang SH, Kang KW, Kim KH, Kwon B, Kim SK, Lee HY, et al. Upregulated HSP27 in human breast cancer cells reduces Herceptin susceptibility by increasing Her2 protein stability. BMC Cancer 2008;8:286.
30. Shetzline SE, Rallapalli R, Dowd KJ, Zou S, Nakata Y, Swider CR, et al. Neuromedin U: a Myb-regulated autocrine growth factor for human myeloid leukemias. Blood 2004;104:1833-40. (Pubitemid 39202294)
31. Euer NI, Kaul S, Deissler H, Mobus VJ, Zeillinger R, Weidle UH. Identification of L1CAM, Jagged2 and Neuromedin U as ovarian cancer-associated antigens. Oncol Rep 2005;13:375-87.
32. Ketterer K, Kong B, Frank D, Giese NA, Bauer A, Hoheisel J, et al. Neuromedin U is overexpressed in pancreatic cancer and increases invasiveness via the hepatocyte growth factor c-Met pathway. Cancer Lett 2009;277:72-81.
33. Takahashi K, Furukawa C, Takano A, Ishikawa N, Kato T, Hayama S, et al. The neuromedin U-growth hormone secretagogue receptor 1b/ neurotensin receptor 1 oncogenic signaling pathway as a therapeutic target for lung cancer. Cancer Res 2006;66:9408-19. (Pubitemid 44623637)
34. Wu Y, McRoberts K, Berr SS, Frierson HF Jr, Conaway M, Theodorescu D. Neuromedin U is regulated by the metastasis suppressor RhoGDI2 and is a novel promoter of tumor formation, lung metastasis and cancer cachexia. Oncogene 2007;26:765-73.
35. Harten SK, Esteban MA, Shukla D, Ashcroft M, Maxwell PH. Inactivation of the von Hippel-Lindau tumour suppressor gene induces Neuromedin U expression in renal cancer cells. Mol Cancer 2011; 10:89.
36. Yamashita K, Upadhyay S, Osada M, Hoque MO, Xiao Y, Mori M, et al. Pharmacologic unmasking of epigenetically silenced tumor suppressor genes in esophageal squamous cell carcinoma. Cancer Cell 2002;2:485-95. (Pubitemid 41043953)
37. Alevizos I, Mahadevappa M, Zhang X, Ohyama H, Kohno Y, Posner M, et al. Oral cancer in vivo gene expression profiling assisted by laser capture microdissection and microarray analysis. Oncogene 2001;20: 6196- 204.
38. Silva J, Garcia V, Garcia JM, Pena C, Dominguez G, Diaz R, et al. Circulating Bmi-1 mRNA as a possible prognostic factor for advanced breast cancer patients. Breast Cancer Res 2007;9:R55.